Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Combined HSC and Kidney Transplantation for CKD and Hematologic Malignancy
NCT07358195Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in hematologic malignancy, sponsored by Massachusetts General Hospital. Primary endpoints: Incidence of full donor chimerism at 24 months, Incidence of Grade IV Toxicity due to Venetoclax and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
venetoclax
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07358195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358195.